Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.
In this paper, a ternary system of albumin-protamine-oligonucleotide nanoparticles (AlPrO-NP) recently developed by Vogel et al. [V. Vogel, D. Lochmann, J. Weyermann, G. Mayer, C. Tziatzios, J.A. van den Broek, W. Haase, D. Wouters, U.S. Schubert, J. Kreuter, A. Zimmer, D. Schubert, Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties and intracellular processing, J. Controlled Rel. (in press)] which could serve as a potential drug delivery system for antisense oligonucleotides. Former studies of binary protamine-oligonucleotide nanoparticles showed two main disadvantages: (i) aggregation of the particles within a few minutes in the presence of salt; (ii) low intracellular dissociation between protamine and oligonucleotide, especially phosphorothioates. To overcome these problems, human serum albumin (HSA) as a non-toxic, biodegradable macromolecule was introduced as protective colloid. The assembly process of AlPrO-NP was investigated by small angle X-ray scattering (SAXS), fluorescence correlation spectroscopy (FCS), photon correlation spectroscopy (PCS) measurements and scanning electron microscopy (SEM). 'Initial complexes' of HSA and protamine sulphate with a mean hydrodynamic diameter (dh) of about 10-14 nm were found. After adding oligonucleotides (unmodified, phosphorothioate DNA and small interfering RNA), nanoparticles (NPs) were assembled in water and in isotonic media with a dh in a range of 230-320 nm for most preparations. The chemical composition of the particles was investigated by high performance liquid chromatography and fluorescence spectrometry. The whole amount of oligonucleotides (30 microg) was entrapped into the particles at a 1:2 mass ratio (oligonucleotide/protamine). Approximately 7-10% (w/w) of the HSA was bound to the particles. The surface charge of the particles ranged from about +12 to -60 mV depending on the protamine concentration and the ionic conditions. The size and the molecular weight of the components, initial complexes and two model NP preparations were calculated from FCS data. These data verified the PCS, SEM and SAXS measurements.
Lochmann
Dirk
D
Institute for Pharmaceutical Technology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Weyermann
Jörg
J
Georgens
Christiane
C
Prassl
Ruth
R
Zimmer
Andreas
A
D055598:Chemical Phenomena; D002627:Chemistry, Physical; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D049329:Nanostructures / Q000737:chemistry*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000737:chemistry*; D011479:Protamines / Q000008:administration & dosage / Q000737:chemistry*; D012542:Scattering, Radiation; D012709:Serum Albumin / Q000008:administration & dosage / Q000737:chemistry*; D013053:Spectrophotometry; D014965:X-Rays
D016376:Oligonucleotides, Antisense; D011479:Protamines; D012709:Serum Albumin